Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The Phosphatidylinositol(4,5)Bisphosphate–Binding Sequence of Transient Receptor Potential Channel Canonical 4α Is Critical for Its Contribution to Cardiomyocyte Hypertrophy

Nicola Cooley, David R. Grubb, Jieting Luo and Elizabeth A. Woodcock
Molecular Pharmacology October 2014, 86 (4) 399-405; DOI: https://doi.org/10.1124/mol.114.093690
Nicola Cooley
Molecular Cardiology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Grubb
Molecular Cardiology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jieting Luo
Molecular Cardiology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A. Woodcock
Molecular Cardiology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 86 no. 4 399-405
DOI 
https://doi.org/10.1124/mol.114.093690
PubMed 
25049082

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received May 12, 2014
  • Accepted July 21, 2014
  • Published online August 27, 2014.

Article Versions

  • Earlier version (July 21, 2014 - 09:18).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Nicola Cooley,
  2. David R. Grubb,
  3. Jieting Luo, and
  4. Elizabeth A. Woodcock
  1. Molecular Cardiology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
  1. Address correspondence to:
    Dr. Elizabeth A. Woodcock, Baker IDI Heart and Diabetes Institute, P.O. Box 6492, St. Kilda Road Central, Melbourne, 8008, Victoria, Australia. E-mail: liz.woodcock{at}bakeridi.edu.au
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: July 2014 to March 2021

AbstractFullPdf
Jul 2014131161
Aug 2014113665
Sep 20143541538
Oct 2014951414
Nov 2014721617
Dec 2014391025
Jan 2015521111
Feb 201522912
Mar 20152775
Apr 20152554
May 20152269
Jun 2015371110
Jul 20153555
Aug 20153935
Sep 201526109
Oct 20151498
Nov 201516810
Dec 201512118
Jan 20161466
Feb 20169128
Mar 2016201111
Apr 201611816
May 2016201715
Jun 201621116
Jul 2016131412
Aug 201615176
Sep 2016201616
Oct 201671910
Nov 2016101110
Dec 20163151
Jan 20173187
Feb 201722812
Mar 20170300
Apr 20170249
May 20171117
Jun 20171257
Jul 20171204
Aug 20172219
Sep 20171138
Oct 20170144
Nov 201732212
Dec 20171171
Jan 201822710
Feb 20182224
Mar 201812314
Apr 201811714
May 20180169
Jun 20180155
Jul 20181179
Aug 201801035
Sep 20182647
Oct 20181436
Nov 201806710
Dec 201805910
Jan 20191669
Feb 201925017
Mar 201901812
Apr 20191515
May 20190109
Jun 20190614
Jul 201971517
Aug 2019068
Sep 2019814
Oct 20191515
Nov 20191432
Dec 20194610
Jan 2020093
Feb 2020075
Mar 20200121
Apr 2020063
May 2020053
Jun 2020143
Jul 20201333
Aug 2020252
Sep 20201215
Oct 20201003
Nov 20201919
Dec 20201017
Jan 20211115
Feb 20212434
Mar 2021600

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 86 (4)
Molecular Pharmacology
Vol. 86, Issue 4
1 Oct 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Phosphatidylinositol(4,5)Bisphosphate–Binding Sequence of Transient Receptor Potential Channel Canonical 4α Is Critical for Its Contribution to Cardiomyocyte Hypertrophy
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

TrpC4α Promotes Hypertrophy

Nicola Cooley, David R. Grubb, Jieting Luo and Elizabeth A. Woodcock
Molecular Pharmacology October 1, 2014, 86 (4) 399-405; DOI: https://doi.org/10.1124/mol.114.093690

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

TrpC4α Promotes Hypertrophy

Nicola Cooley, David R. Grubb, Jieting Luo and Elizabeth A. Woodcock
Molecular Pharmacology October 1, 2014, 86 (4) 399-405; DOI: https://doi.org/10.1124/mol.114.093690
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of Celecoxib targets by label-free TPP
  • Editing TOP2α Intron 19 5′ SS Circumvents Drug Resistance
  • CTS Bias
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics